Literature DB >> 17044026

Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA.

Maria Berndtsson1, Maria Hägg, Theocharis Panaretakis, Aleksandra Mandic Havelka, Maria C Shoshan, Stig Linder.   

Abstract

Cisplatin is a broad-spectrum anticancer drug that is also widely used in experimental studies on DNA damage-induced apoptosis. Induction of apoptosis within 24-48 hr requires cisplatin concentrations that are at least one order of magnitude higher than the IC(50). Here, we show that such high, apoptosis-inducing cisplatin concentrations induce cellular superoxide formation and that apoptosis is inhibited by superoxide scavengers. The same concentration limit and the requirement for superoxide are also true for induction of caspase activation in enucleated cells (cytoplasts), showing that cisplatin-induced apoptosis occurs independently of nuclear DNA damage. In contrast, lower cisplatin concentrations, which do not induce acute apoptosis, are sufficient for induction of DNA damage signaling. We propose that the antiproliferative effects of cisplatin at IC(50) doses involve premature senescence and secondary, nonstress-induced apoptosis. The higher doses currently used in in vitro studies lead to acute, stress-induced apoptosis that involves induction of superoxide but is largely DNA damage-independent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17044026     DOI: 10.1002/ijc.22132

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  87 in total

Review 1.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons.

Authors:  Yanlin Jiang; Chunlu Guo; Michael R Vasko; Mark R Kelley
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 3.  Cellular redox pathways as a therapeutic target in the treatment of cancer.

Authors:  Alberto J Montero; Jacek Jassem
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

4.  Modulation of tumor necrosis factor-mediated cell death by fullerenes.

Authors:  Ljubica Harhaji; Aleksandra Isakovic; Ljubica Vucicevic; Kristina Janjetovic; Maja Misirkic; Zoran Markovic; Biljana Todorovic-Markovic; Nadezda Nikolic; Sanja Vranjes-Djuric; Zoran Nikolic; Vladimir Trajkovic
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

Review 5.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

6.  A knockdown with smoke model reveals FHIT as a repressor of Heme oxygenase 1.

Authors:  Jennifer A Boylston; Charles Brenner
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.

Authors:  Judith Michels; Ilio Vitale; Laura Senovilla; David P Enot; Pauline Garcia; Delphine Lissa; Ken A Olaussen; Catherine Brenner; Jean-Charles Soria; Maria Castedo; Guido Kroemer
Journal:  Cell Cycle       Date:  2013-02-21       Impact factor: 4.534

Review 8.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

9.  Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.

Authors:  Victoria Hellberg; Inger Wallin; Sofi Eriksson; Emma Hernlund; Elin Jerremalm; Maria Berndtsson; Staffan Eksborg; Elias S J Arnér; Maria Shoshan; Hans Ehrsson; Göran Laurell
Journal:  J Natl Cancer Inst       Date:  2008-12-30       Impact factor: 13.506

10.  Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.

Authors:  D L Roberts; K J Williams; R L Cowen; M Barathova; A J Eustace; S Brittain-Dissont; M J Tilby; D G Pearson; C J Ottley; I J Stratford; C Dive
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.